These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1752746)

  • 21. Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors.
    Little MP
    Int J Radiat Biol; 1997 Dec; 72(6):715-26. PubMed ID: 9416794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk coefficient for gamma-rays with regard to solid cancer.
    Kellerer AM; Walsh L; Nekolla EA
    Radiat Environ Biophys; 2002 Jun; 41(2):113-23. PubMed ID: 12201054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response relationship of neutrons and gamma rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950--1971.
    Ishimaru T; Otake M; Ischimaru M
    Radiat Res; 1979 Feb; 77(2):377-94. PubMed ID: 286375
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessing the impact of different neutron RBEs on the all solid cancer radiation risks obtained from the Japanese A-bomb survivors data.
    Hafner L; Walsh L; Rühm W
    Int J Radiat Biol; 2023; 99(4):629-643. PubMed ID: 36154910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corrections in the atomic bomb data to examine low dose risk.
    Baker GS; Hoel DG
    Health Phys; 2003 Dec; 85(6):709-20. PubMed ID: 14626322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RELATIVE BIOLOGICAL EFFECTIVENESS OF NEUTRONS DERIVED FROM THE EXCESS RELATIVE RISK MODEL WITH THE ATOMIC BOMB SURVIVORS DATA MANAGED BY HIROSHIMA UNIVERSITY.
    Satoh K; Yasuda H; Kawakami H; Tashiro S
    Radiat Prot Dosimetry; 2018 Aug; 180(1-4):346-350. PubMed ID: 29036656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutron relative biological effectiveness for solid cancer incidence in the Japanese A-bomb survivors: an analysis considering the degree of independent effects from γ-ray and neutron absorbed doses with hierarchical partitioning.
    Walsh L
    Radiat Environ Biophys; 2013 Mar; 52(1):29-36. PubMed ID: 23161400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental derivation of relative biological effectiveness of A-bomb neutrons in Hiroshima and Nagasaki and implications for risk assessment.
    Sasaki MS; Nomura T; Ejima Y; Utsumi H; Endo S; Saito I; Itoh T; Hoshi M
    Radiat Res; 2008 Jul; 170(1):101-17. PubMed ID: 18582156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy.
    Schneider U; Walsh L
    Radiat Environ Biophys; 2008 Apr; 47(2):253-63. PubMed ID: 18157543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current risk estimates based on the A-bomb survivors data - a discussion in terms of the ICRP recommendations on the neutron weighting factor.
    Rühm W; Walsh L
    Radiat Prot Dosimetry; 2007; 126(1-4):423-31. PubMed ID: 17533156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct biological evidence for a significant neutron dose to survivors of the Hiroshima atomic bomb.
    Brenner DJ
    Radiat Res; 1996 Apr; 145(4):501-7. PubMed ID: 8600511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Radiation risks. Results of the new evaluation].
    Kellerer AM
    Radiologe; 1991 May; 31(5):227-34. PubMed ID: 1876693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discussion of uncertainties and the impact of different neutron RBEs on all solid cancer radiation incidence risks obtained from the Japanese A-bomb survivor data.
    Hafner L; Walsh L; Rühm W
    Ann ICRP; 2023 Mar; 52(1-2):17-22. PubMed ID: 38143299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer risk estimates for gamma-rays with regard to organ-specific doses Part II: site-specific solid cancers.
    Walsh L; Rühm W; Kellerer AM
    Radiat Environ Biophys; 2004 Dec; 43(4):225-31. PubMed ID: 15645312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal analysis of a dose-response relationship: leukemia mortality in atomic bomb survivors.
    Brodsky JB; Groer PG; Liddell R; Ishimaru T; Ichimaru M
    Radiat Res; 1984 Sep; 99(3):547-61. PubMed ID: 6473713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reassessment of the cancer mortality risk among Hiroshima atomic-bomb survivors using a new dosimetry system, ABS2000D, compared with ABS93D.
    Katayama H; Matsuura M; Endo S; Hoshi M; Ohtaki M; Hayakawa N
    J Radiat Res; 2002 Mar; 43(1):53-64. PubMed ID: 12056330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The shape of the cancer mortality dose-response curve for the A-bomb survivors.
    Pierce DA; Vaeth M
    Radiat Res; 1991 Apr; 126(1):36-42. PubMed ID: 2020737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignancies in atomic bomb survivors in Hiroshima and Nagasaki.
    Shimaoka K; Akiba S
    J Nucl Med Allied Sci; 1990; 34(4):254-9. PubMed ID: 2090789
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk estimation for fast neutrons with regard to solid cancer.
    Kellerer AM; Walsh L
    Radiat Res; 2001 Dec; 156(6):708-17. PubMed ID: 11741494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship of gamma and neutron radiation to posterior lenticular opacities among atomic bomb survivors in Hiroshima and Nagasaki.
    Otake M; Schull WJ
    Radiat Res; 1982 Dec; 92(3):574-95. PubMed ID: 7178422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.